Elranatamab History and Updates

157 events · 2019 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 12, 2026.

FDA Approvals

Label Revisions

149

Trial Milestones

Pivotal Publications

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-12Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Elranatamab since 2019, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (5)

2026

Label revisionElranatamab: FDA Adds Boxed Warning for CRS and Neurotoxicity on May 14, 2026· May 14, 2026
Primary completionElranatamab Phase 3 Trial for Multiple Myeloma Reaches Primary Completion· Apr 27, 2026
Results postedElranatamab Multiple Myeloma Combination Trial Terminated, DLTs Reported· Feb 23, 2026

2025

FDA approval (supplemental)Elrexfio Supplemental Application Approved by FDA for Efficacy· Jul 10, 2025
Results postedElranatamab Shows Improved Progression-Free Survival in Multiple Myeloma· Jun 27, 2025

Upcoming & expected milestones

Primary completionAug 1, 2026· ClinicalTrials.gov

Phase 2 primary completion: NCT06138275

Elranatamab in R/R Multiple Myeloma

Primary completionAug 30, 2026· ClinicalTrials.gov

Phase 3 primary completion: NCT06152575

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Ta

Trial startedAug 31, 2026· ClinicalTrials.gov

Phase 2 trial started: NCT07637578

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Primary completionOct 1, 2026· ClinicalTrials.gov

Phase 1/Phase 2 primary completion: NCT06645678

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Primary completionDec 1, 2026· ClinicalTrials.gov

Phase 2 primary completion: NCT06832865

ELISA in Relapsed/Refractory MM

Primary completionDec 1, 2026· ClinicalTrials.gov

Phase 2 primary completion: NCT06015542

Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

Primary completionDec 31, 2026· ClinicalTrials.gov

Phase 2 primary completion: NCT06421675

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Primary completionMar 31, 2027· ClinicalTrials.gov

Phase 1/Phase 2 primary completion: NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Trial startedMar 31, 2027· ClinicalTrials.gov

Phase 4 trial started: NCT07474961

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

Primary completionApr 10, 2027· ClinicalTrials.gov

Phase 1 primary completion: NCT06215118

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Mu

Primary completionMay 31, 2027· ClinicalTrials.gov

Phase 1/Phase 2 primary completion: NCT06988488

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With

Primary completionJul 31, 2027· ClinicalTrials.gov

Phase 2 primary completion: NCT06183489

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Primary completionJul 31, 2027· ClinicalTrials.gov

Phase 1 primary completion: NCT05927571

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed

Primary completionAug 4, 2027· ClinicalTrials.gov

Phase 3 primary completion: NCT05317416

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Primary completionAug 16, 2027· ClinicalTrials.gov

Phase 1/Phase 2 primary completion: NCT06106945

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Primary completionSep 1, 2027· ClinicalTrials.gov

Phase 1/Phase 2 primary completion: NCT06569147

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Primary completionJul 18, 2028· ClinicalTrials.gov

Primary completion: NCT07320326

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Primary completionAug 1, 2028· ClinicalTrials.gov

Phase 1 primary completion: NCT06121843

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participa

Primary completionSep 1, 2028· ClinicalTrials.gov

Phase 1 primary completion: NCT06799026

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refract

Primary completionDec 31, 2028· ClinicalTrials.gov

Phase 2 primary completion: NCT07382739

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Ext

Primary completionDec 31, 2028· ClinicalTrials.gov

Phase 1 primary completion: NCT07280013

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Primary completionJan 31, 2029· ClinicalTrials.gov

Primary completion: NCT06855121

The Norwegian Immunotherapy in Multiple Myeloma Study

Primary completionApr 30, 2029· ClinicalTrials.gov

Phase 2 primary completion: NCT06947083

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Primary completionAug 27, 2029· ClinicalTrials.gov

Phase 2 primary completion: NCT07454382

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Primary completionOct 31, 2029· ClinicalTrials.gov

Phase 2 primary completion: NCT07637578

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Primary completionDec 31, 2029· ClinicalTrials.gov

Phase 2 primary completion: NCT06207799

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Primary completionDec 31, 2029· ClinicalTrials.gov

Phase 2 primary completion: NCT06711705

Elranatamab in Relapsed/Refractory Multiple Myeloma

Primary completionJan 31, 2030· ClinicalTrials.gov

Primary completion: NCT06581848

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Primary completionSep 30, 2030· ClinicalTrials.gov

Phase 2 primary completion: NCT06997081

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Primary completionOct 18, 2030· ClinicalTrials.gov

Phase 3 primary completion: NCT05623020

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Le

Primary completionNov 30, 2030· ClinicalTrials.gov

Phase 2 primary completion: NCT06931704

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly

Primary completionDec 1, 2030· ClinicalTrials.gov

Phase 2 primary completion: NCT07247097

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Primary completionFeb 22, 2032· ClinicalTrials.gov

Phase 4 primary completion: NCT06057402

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Primary completionNov 30, 2032· ClinicalTrials.gov

Phase 2 primary completion: NCT06974786

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification t

Primary completionMay 31, 2036· ClinicalTrials.gov

Phase 3 primary completion: NCT06918002

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible N

Primary completionDec 31, 2036· ClinicalTrials.gov

Phase 4 primary completion: NCT07474961

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

Past events

2026

Trial registeredJun 10, 2026· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT07637578

A Phase II Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Label revisionMay 14, 2026· FDA

Boxed warning present on label on Elrexfio label (effective 2026-05-14)

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME • Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving EL

Primary completionApr 27, 2026· ClinicalTrials.gov

Phase 3 primary completion: NCT05020236

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Tre

Trial startedApr 15, 2026· ClinicalTrials.gov

Phase 2 trial started: NCT07247097

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Trial startedMar 31, 2026· ClinicalTrials.gov

Phase 2 trial started: NCT07382739

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Ext

FDA approval (supplemental)Mar 25, 2026· FDA

FDA approved supplemental application for Elrexfio (elranatamab-bcmm) — REMS (BLA 761345 S-9)

Sponsor: PFIZER INC. Class: REMS.

Trial registeredMar 16, 2026· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT07474961

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

Trial registeredMar 6, 2026· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT07454382

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Trial startedFeb 27, 2026· ClinicalTrials.gov

Phase 2 trial started: NCT07454382

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Results postedFeb 23, 2026· ClinicalTrials.gov

Trial results posted: NCT05090566

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

FDA approval (supplemental)Feb 19, 2026· FDA

FDA approved supplemental application for Elrexfio (elranatamab-bcmm) — Labeling (BLA 761345 S-7)

Sponsor: PFIZER INC. Class: Labeling.

Trial startedFeb 6, 2026· ClinicalTrials.gov

Phase 1 trial started: NCT07280013

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Trial registeredFeb 3, 2026· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT07382739

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Ext

Trial registeredJan 6, 2026· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07320326

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

2025

Trial startedDec 30, 2025· ClinicalTrials.gov

Trial started: NCT07320326

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Trial registeredDec 12, 2025· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT07280013

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Trial registeredNov 25, 2025· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT07247097

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Trial startedOct 7, 2025· ClinicalTrials.gov

Phase 1/Phase 2 trial started: NCT06988488

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With

Trial startedSep 16, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT06997081

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Trial startedAug 14, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT06832865

ELISA in Relapsed/Refractory MM

Trial startedAug 8, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT06974786

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification t

FDA approval (supplemental)Jul 10, 2025· FDA

FDA approved supplemental application for Elrexfio (elranatamab-bcmm) — Efficacy (BLA 761345 S-3)

Sponsor: PFIZER INC. Class: Efficacy.

Trial startedJul 9, 2025· ClinicalTrials.gov

Phase 3 trial started: NCT06918002

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible N

FDA approval (supplemental)Jul 8, 2025· FDA

FDA approved supplemental application for Elrexfio (elranatamab-bcmm) — Labeling (BLA 761345 S-4)

Sponsor: PFIZER INC. Class: Labeling.

Primary completionJul 7, 2025· ClinicalTrials.gov

Phase 1 primary completion: NCT05675449

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multi

Results postedJun 27, 2025· ClinicalTrials.gov

Trial results posted: NCT06504524

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany

Trial startedJun 5, 2025· ClinicalTrials.gov

Trial started: NCT06581848

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Primary completionMay 31, 2025· ClinicalTrials.gov

Phase 2 primary completion: NCT06282978

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Primary completionMay 30, 2025· ClinicalTrials.gov

Phase 2 primary completion: NCT06282978

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Trial registeredMay 30, 2025· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06997081

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Trial startedMay 27, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT06947083

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Trial registeredMay 25, 2025· ClinicalTrials.gov

Phase 1/Phase 2 trial registered on ClinicalTrials.gov: NCT06988488

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With

Trial registeredMay 16, 2025· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06974786

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification t

Trial startedMay 1, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT06931704

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly

Trial registeredApr 27, 2025· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06947083

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Trial registeredApr 17, 2025· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06931704

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly

Trial registeredApr 9, 2025· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06918002

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible N

Trial startedMar 28, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT06421675

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Primary completionMar 3, 2025· ClinicalTrials.gov

Primary completion: NCT06592222

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared

Trial registeredMar 3, 2025· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06855121

The Norwegian Immunotherapy in Multiple Myeloma Study

Trial registeredFeb 18, 2025· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06832865

ELISA in Relapsed/Refractory MM

Primary completionFeb 13, 2025· ClinicalTrials.gov

Phase 2 primary completion: NCT05090566

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Trial startedJan 31, 2025· ClinicalTrials.gov

Phase 1 trial started: NCT06799026

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refract

Trial startedJan 29, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT06015542

Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

Trial registeredJan 29, 2025· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT06799026

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refract

Trial startedJan 15, 2025· ClinicalTrials.gov

Trial started: NCT06855121

The Norwegian Immunotherapy in Multiple Myeloma Study

2024

Trial startedDec 18, 2024· ClinicalTrials.gov

Phase 2 trial started: NCT06711705

Elranatamab in Relapsed/Refractory Multiple Myeloma

Trial registeredDec 2, 2024· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06711705

Elranatamab in Relapsed/Refractory Multiple Myeloma

Trial startedNov 26, 2024· ClinicalTrials.gov

Phase 1/Phase 2 trial started: NCT06645678

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Trial startedNov 1, 2024· ClinicalTrials.gov

Phase 1/Phase 2 trial started: NCT06569147

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Results postedOct 29, 2024· ClinicalTrials.gov

Trial results posted: NCT05932290

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Trial registeredOct 17, 2024· ClinicalTrials.gov

Phase 1/Phase 2 trial registered on ClinicalTrials.gov: NCT06645678

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Results postedSep 27, 2024· ClinicalTrials.gov

Trial results posted: NCT04798586

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Results postedSep 19, 2024· ClinicalTrials.gov

Trial results posted: NCT05228470

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Trial registeredSep 19, 2024· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06592222

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared

FDA approval (supplemental)Sep 10, 2024· FDA

FDA approved supplemental application for Elrexfio (elranatamab-bcmm) — REMS (BLA 761345 S-2)

Sponsor: PFIZER INC. Class: REMS.

Trial registeredSep 3, 2024· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06581848

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Trial startedAug 26, 2024· ClinicalTrials.gov

Trial started: NCT06592222

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared

Trial registeredAug 23, 2024· ClinicalTrials.gov

Phase 1/Phase 2 trial registered on ClinicalTrials.gov: NCT06569147

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Results postedJul 30, 2024· ClinicalTrials.gov

Trial results posted: NCT05014412

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatme

Trial startedJul 17, 2024· ClinicalTrials.gov

Phase 2 trial started: NCT06207799

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Trial registeredJul 16, 2024· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06504524

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany

Primary completionMay 31, 2024· ClinicalTrials.gov

Primary completion: NCT06504524

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany

Trial registeredMay 20, 2024· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06421675

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Trial startedMay 14, 2024· ClinicalTrials.gov

Phase 2 trial started: NCT06183489

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Results postedApr 22, 2024· ClinicalTrials.gov

Trial results posted: NCT05565391

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Trial startedMar 8, 2024· ClinicalTrials.gov

Phase 2 trial started: NCT06138275

Elranatamab in R/R Multiple Myeloma

Trial registeredFeb 28, 2024· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06282978

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Trial startedFeb 22, 2024· ClinicalTrials.gov

Phase 1 trial started: NCT06121843

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participa

Trial startedFeb 20, 2024· ClinicalTrials.gov

Phase 1 trial started: NCT06215118

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Mu

Trial startedFeb 8, 2024· ClinicalTrials.gov

Phase 3 trial started: NCT06152575

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Ta

Trial registeredJan 22, 2024· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT06215118

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Mu

Trial registeredJan 17, 2024· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06207799

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

2023

Trial registeredDec 27, 2023· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06183489

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

FDA approval (supplemental)Dec 13, 2023· FDA

FDA approved supplemental application for Elrexfio (elranatamab-bcmm) — REMS (BLA 761345 S-1)

Sponsor: PFIZER INC. Class: REMS.

Trial startedDec 5, 2023· ClinicalTrials.gov

Phase 1/Phase 2 trial started: NCT06106945

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Trial registeredNov 30, 2023· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06152575

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Ta

Trial startedNov 23, 2023· ClinicalTrials.gov

Phase 2 trial started: NCT06282978

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Trial registeredNov 18, 2023· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06138275

Elranatamab in R/R Multiple Myeloma

Trial registeredNov 8, 2023· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT06121843

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participa

Trial registeredOct 30, 2023· ClinicalTrials.gov

Phase 1/Phase 2 trial registered on ClinicalTrials.gov: NCT06106945

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Results postedOct 25, 2023· ClinicalTrials.gov

Trial results posted: NCT04649359

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, On

Trial startedOct 3, 2023· ClinicalTrials.gov

Phase 4 trial started: NCT06057402

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Trial registeredSep 28, 2023· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT06057402

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Trial startedSep 1, 2023· ClinicalTrials.gov

Trial started: NCT06504524

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany

Trial registeredAug 29, 2023· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06015542

Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

FDA approvalAug 14, 2023· FDA

FDA approved Elrexfio (elranatamab-bcmm) (BLA 761345)

Sponsor: PFIZER INC. Class: Type 1 - New Molecular Entity.

Trial startedAug 10, 2023· ClinicalTrials.gov

Phase 1 trial started: NCT05927571

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed

Primary completionAug 6, 2023· ClinicalTrials.gov

Phase 2 primary completion: NCT05228470

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Primary completionJul 12, 2023· ClinicalTrials.gov

Primary completion: NCT05932290

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Trial registeredJul 6, 2023· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT05932290

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Trial registeredJul 3, 2023· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05927571

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed

Primary completionJun 15, 2023· ClinicalTrials.gov

Phase 2 primary completion: NCT05014412

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatme

Trial startedJun 1, 2023· ClinicalTrials.gov

Trial started: NCT05932290

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Trial registeredJan 9, 2023· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05675449

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multi

2022

Trial startedDec 14, 2022· ClinicalTrials.gov

Phase 1 trial started: NCT05675449

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multi

Trial registeredNov 21, 2022· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT05623020

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Le

Trial startedNov 10, 2022· ClinicalTrials.gov

Phase 3 trial started: NCT05623020

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Le

Primary completionNov 4, 2022· ClinicalTrials.gov

Primary completion: NCT05565391

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Trial registeredOct 4, 2022· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT05565391

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Trial startedOct 3, 2022· ClinicalTrials.gov

Trial started: NCT05565391

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Trial registeredJul 18, 2022· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT05462639

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Primary completionJun 17, 2022· ClinicalTrials.gov

Phase 2 primary completion: NCT04649359

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, On

Primary completionMay 27, 2022· ClinicalTrials.gov

Phase 1 primary completion: NCT04798586

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Trial registeredApr 7, 2022· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT05317416

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Trial startedMar 25, 2022· ClinicalTrials.gov

Phase 3 trial started: NCT05317416

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Trial registeredFeb 14, 2022· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT05238311

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Trial registeredFeb 8, 2022· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT05228470

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

2021

Trial startedDec 21, 2021· ClinicalTrials.gov

Phase 2 trial started: NCT05228470

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Trial startedOct 27, 2021· ClinicalTrials.gov

Phase 2 trial started: NCT05090566

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Trial registeredOct 25, 2021· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT05090566

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Trial startedOct 7, 2021· ClinicalTrials.gov

Phase 2 trial started: NCT05014412

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatme

Trial startedOct 4, 2021· ClinicalTrials.gov

Phase 3 trial started: NCT05020236

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Tre

Trial registeredAug 25, 2021· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT05020236

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Tre

Trial registeredAug 20, 2021· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT05014412

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatme

Trial startedMar 22, 2021· ClinicalTrials.gov

Phase 1 trial started: NCT04798586

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Trial registeredMar 15, 2021· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT04798586

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Trial startedFeb 2, 2021· ClinicalTrials.gov

Phase 2 trial started: NCT04649359

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, On

2020

Trial registeredDec 2, 2020· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT04649359

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, On

2019

Trial registeredAug 28, 2019· ClinicalTrials.gov

Phase 1/Phase 2 trial registered on ClinicalTrials.gov: NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Trial startedAug 9, 2019· ClinicalTrials.gov

Phase 1/Phase 2 trial started: NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.